Mylan's Chairman Was Paid $97.6 Million


It was a year when the company’s CEO was called to testify before Congress to defend the pricing of its EpiPen. It was a year when the company’s stock price plummeted 29%. It was a year when the company’s share of the auto-injector market fell 25%.

Yet 2016 was a year when Mylan’s chairman, Robert J Coury, received over $97 million in compensation, including a $20 million bonus and over $22 million in “transition payments” for stepping down as an officer of the company.

Last year, Mylan’s CEO, Heather Bresch, was paid $13.8 million, down 27% from the year before.

The compensation figures were disclosed Monday in a filing with the Securities and Exchange Commission.

Click to visit sponsor

The company is currently the subject of a class-action lawsuit by consumers alleging Mylan engaged in racketeering when it colluded with pharmacy benefit managers to keep the price of EpiPen high.

Last week, Sanofi filed suit against the Mylan alleging the company illegally blocked introduction of Auvi-Q, Sanofi’s competitor to the EpiPen.

Print or share this article

Print or share this article
Click to visit sponsor
Dave Bloom
Dave Bloom
Dave Bloom is CEO and "Blogger in Chief" of

Find Allergy-Friendly Products


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.